Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.
Lancet
; 383(9923): 1138-46, 2014 Mar 29.
Article
in En
| MEDLINE
| ID: mdl-24412048
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Transfection
/
Genetic Therapy
/
Infectious Anemia Virus, Equine
/
Genetic Vectors
/
Antiparkinson Agents
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2014
Document type:
Article